Feb 26,2024 TOP STORY

GE HealthCare and Biofourmis Collaborate to Extend Patient Monitoring Outside the Hospital with Virtual Care-at-Home Solutions

GE HealthCare and Biofourmis have announced a strategic collaboration aimed at enhancing continuity of care by enabling safe, effective, and accessible care in the home to support the patient journey beyond the hospital setting. The goal of the GE HealthCare-Biofourmis collaboration is to enable more patients to go home earlier, and offer an alternative to facility-based care with the comfort and peace of mind that they are receiving high quality care at home. GE HealthCare’s FlexAcuity™ monitoring solutions in combination with GE HealthCare’s virtual care solutions like Mural ICU, Command Center and Digital CMU adapt to rapidly changing patient needs in the hospital and are built on a legacy of innovation. By offering Biofourmis’ virtual care-at-home solutions to customers, GE HealthCare can extend the care continuum beyond the hospital, and care teams can have a longitudinal patient view beyond the hospital setting. GE HealthCare will begin distributing Biofourmis solutions to customers in the United States starting Q1 2024.

COLLABORATION PARTNERSHIP

#institution

#virtual care

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 16,2021

Resilience Raises €5M To Accelerate the Development of Its Remote Patient Monitoring Platform in Oncology

Resilience is a new startup wants to help cancer treatment institutes as well as cancer patients at every step of the treatment journey. They recently raised a $6 million funding round (€5 million) led by Singular, the VC firm founded by former Alven partners Raffi Kamber and Jérémy Uzan. Tech business angels Nathalie Balla (La Redoute), Xavier Niel (Free), Jean-Charles Samuelian (Alan), Roxanne Varza (Station F) and more are also participating. There are also some healthcare investors in today’s funding round, such as Charles Ferté (AstraZeneca), Philippe Dabi (Bioclinic) and Thomas Clozel (Owkin). Resilience wants to become a full-stack software solution for cancer treatment for both the medical team and patients. When it comes to practitioners, Resilience will be a software-as-a-service solution that can augment therapeutic decisions. When it comes to patients, there will be a web and mobile app to access content and information about their cancer. In particular, Resilience could help you understand side effects and treat them.

FUNDING SEED ROUND

#rpm

View Analyst & Ambassador Comments
Go to original news
Jan 25,2022

French Healthtech Resilience Raises €40 Million to Improve the Care Pathway for Cancer Patients

After a €5M financing in 2021, Resilience announces a €40M Series A round led by the global investment firm Cathay Innovation with strong support from the French VC Singular. Three European funds: Exor Seeds, Picus Capital and Seaya Ventures are also participating in the round as well as a consortium of healthcare players: Fondation Santé Service, MACSF, Ramsay Santé and Vivalto Ventures. This funding will allow the company to accelerate the deployment of its medical devices (CE Class IIa) in healthcare institutions and to enrich its application with new functionalities dedicated to the well-being of patients. Co-founded less than a year ago by two tech entrepreneurs, Céline Lazorthes and Jonathan Benhamou, in partnership with the Gustave Roussy Institute, the 5th largest cancer center in the world, Resilience’s mission is to reinvent the way we treat cancer through digital and remote medical monitoring.

FUNDING SERIES A

#rpm

View Analyst & Ambassador Comments
Go to original news
Jan 24,2024 TOP STORY

Sciensus acquires oncology symptom tracker app Vinehealth

UK-based pharmaceutical supply company, Sciensus, has announced that it has acquired the cancer patient support app, Vinehealth, with the aim of using data collected from the app to support what the company calls actionable insights. The Vinehealth App is an oncology platform designed to allow users to report and track symptoms of disease progression in real time, whilst allowing that same data to be shared with clinicians. The app joins Sciensus’ roster of telehealth and remote patient monitoring apps including the company’s own InTouch app. It also adds further support for oncology patients to the company’s remit, which already covers more than 50 indications digitally.

COLLABORATION MERGERS & ACQUISITION

#product & service

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Jan 18,2024

Biofourmis Launches In-Home Service Ecosystem to Transform Care Delivery

Biofourmis announced the launch of its in-home service ecosystem. The platform empowers healthcare providers and biopharma companies to seamlessly integrate a diverse range of in-home services into their care programs, bringing essential care directly to patients and optimizing efficiency for clinicians. The company's vision about the new service offering is to create a single, unified platform where people can order, schedule, and track a comprehensive menu of in-home services, from nursing and phlebotomy to durable medical equipment and imaging. Biofourmis makes this vision a reality with its integrated platform, supporting both Biofourmis Care™ and Biofourmis Connect™ solutions. In-home services are currently available throughout the US and can be fully customized to your specific requirements.

PRODUCT

#rpm

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jan 18,2024

Biofourmis Launches In-Home Service Ecosystem to Transform Care Delivery

Biofourmis announced the launch of its in-home service ecosystem. The platform empowers healthcare providers and biopharma companies to seamlessly integrate a diverse range of in-home services into their care programs, bringing essential care directly to patients and optimizing efficiency for clinicians. The company's vision about the new service offering is to create a single, unified platform where people can order, schedule, and track a comprehensive menu of in-home services, from nursing and phlebotomy to durable medical equipment and imaging. Biofourmis makes this vision a reality with its integrated platform, supporting both Biofourmis Care™ and Biofourmis Connect™ solutions. In-home services are currently available throughout the US and can be fully customized to your specific requirements.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
Jan 30,2024 TOP STORY

Reimagine Care and Michiana Hematology Oncology Partnership Extends Cancer Care into the Homes of Patients of the Largest Cancer Provider in the Region

Reimagine Care, the nation’s leading provider of virtual-first cancer care, announces a partnership with Michiana Hematology Oncology (MHO) to extend its cancer care services beyond the walls of the clinic. This partnership represents a significant step towards a more patient-centric treatment experience by integrating clinical oncology experts with technology to support MHO’s patients around the clock. By combining Reimagine Care's virtual, digital, and data capabilities with MHO's expertise in hematology and oncology, the collaboration aims to break down barriers to access and transform the way patients receive treatment. MHO patients will have the ability discuss treatment plans, ask questions, manage symptoms, and receive personalized care with Reimagine Care’s oncology advanced practice providers and registered nurses through SMS text, call, and video consultations.

COLLABORATION PARTNERSHIP

#institution

#virtual care

#rpm

View Analyst & Ambassador Comments
Go to original news
Jan 31,2024 TOP STORY

VBC enabler Valendo Health launches for endocrinologists to provide 'across the board' diabetes care

A new value-based care enabler Valendo Health focused on endocrinology has launched with a mission to shape the future of diabetes care. Valendo Health uses a phased approach to offer expertise, technology and data-rich tools to help independent physicians enhance clinical capacity, streamline operations and transition to value-based care. The startup has announced two initial provider partners: Cecelia Health, a virtual provider for chronic care management, and Advanced Metabolic Care + Research (AMCR), an endocrinology center in Southern California. Through its partnership with Cecelia, Valendo can offer practices like AMCR access to multilingual diabetes educators, nutritionists, nurses and other clinicians “to make sure we can provide care across the board in every community across the country,” CEO Dave Terry said. To date, Cecelia has contracted with large payers, health system and pharma companies—not smaller practices like ACMR. Valendo is now helping it to do so and to learn about the risk-taking business should it decide to pursue value-based arrangements in the future.

COLLABORATION PARTNERSHIP

#institution

#telehealth

#rpm

View Analyst & Ambassador Comments
Go to original news
Jan 31,2024

Endocrinology company Valendo Health launches with $4M and two provider partners

Valendo Health, a diabetes-focused, value-based endocrinology company, announced its launch with $4 million in seed funding and two providers. The company, built out of Redesign Health, aims to increase revenue for endocrinologists while assisting with the transition to a value-based care model. It offers telehealth and remote patient monitoring services with diabetes care clinicians, an endocrinology-focused EMR, data analytics and assistance with implementing value-based care contracting. The Boston-based company has partnered with two providers: Cecelia Health, a national virtual specialty care provider for chronic care management, and Advanced Metabolic Care + Research, an endocrinology center in Southern California serving patients with diabetes and other metabolic conditions. "At Valendo, we provide endocrinologists the tools to increase clinical capacity and grow practice revenue through virtual care and practice management support, and then we help them transition into value-based contracts." said Dave Terry, CEO and cofounder of Valendo Health.

FUNDING SEED ROUND

#telehealth

#rpm

View Analyst & Ambassador Comments
Go to original news
Jan 18,2024 TOP STORY

Aptar Digital Health and Moffitt Cancer Center Launch Clinical Evaluation for Oncology Digital Therapeutic, Oleena®

Aptar Digital Health announced a collaboration with Moffitt Cancer Center, a leading U.S. cancer care and research institution, to conduct a clinical evaluation of Oleena®, Aptar Digital Health’s FDA approved and CE-marked digital therapeutic (DTx) for the management of symptoms in cancer care. The clinical evaluation, which will begin in February 2024 and run for a total period of 15 months, will primarily assess the usability of Oleena® by measuring key indicators such as patient satisfaction and engagement, as well as clinical outcomes including symptom burden, anti-cancer treatment adherence and quality of life. Under this clinical evaluation, head and neck cancer patients being treated with chemoradiation will use Aptar Digital Health’s Oleena® DTx to guide them in self-managing their symptoms.

COLLABORATION PARTNERSHIP

#r&d

#dtx

#rpm

View Analyst & Ambassador Comments
Go to original news
Subscribe to RPM